NYSE:DGXHealthcare
Do Wall Street’s DGX Ratings Reveal a Durable Edge in Diversified Diagnostics for Quest?
In recent days, Quest Diagnostics has attracted favorable attention from Wall Street, with analysts issuing 9 buy and 9 hold ratings and no sell calls, reflecting confidence in its broad portfolio of diagnostic testing and healthcare services across the United States.
This cluster of positive opinions highlights how Quest’s diversified offering and perceived financial resilience are shaping analyst views on its role in an evolving healthcare landscape.
We’ll now examine how this upbeat...